AU2001296435A1 - Topoisomerase inhibitors - Google Patents

Topoisomerase inhibitors

Info

Publication number
AU2001296435A1
AU2001296435A1 AU2001296435A AU9643501A AU2001296435A1 AU 2001296435 A1 AU2001296435 A1 AU 2001296435A1 AU 2001296435 A AU2001296435 A AU 2001296435A AU 9643501 A AU9643501 A AU 9643501A AU 2001296435 A1 AU2001296435 A1 AU 2001296435A1
Authority
AU
Australia
Prior art keywords
formula
alkyl
mmol
mixture
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296435A
Other languages
English (en)
Inventor
Carol Bachand
Neekakantan Balasubramanian
Francis Beaulieu
David B. Frennesson
Mikael Mahler
Edward H. Ruediger
Mark G. Saulnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2001296435A1 publication Critical patent/AU2001296435A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001296435A 2000-10-06 2001-10-01 Topoisomerase inhibitors Abandoned AU2001296435A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23872600P 2000-10-06 2000-10-06
US60/238,726 2000-10-06
PCT/US2001/030640 WO2002030941A2 (en) 2000-10-06 2001-10-01 Topoisomerase inhibitors

Publications (1)

Publication Number Publication Date
AU2001296435A1 true AU2001296435A1 (en) 2002-04-22

Family

ID=22899064

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296435A Abandoned AU2001296435A1 (en) 2000-10-06 2001-10-01 Topoisomerase inhibitors

Country Status (7)

Country Link
US (1) US6677450B2 (https=)
EP (1) EP1326874A2 (https=)
JP (1) JP2004523478A (https=)
AU (1) AU2001296435A1 (https=)
CA (1) CA2424971A1 (https=)
HU (1) HUP0303279A3 (https=)
WO (1) WO2002030941A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
WO2008076394A1 (en) * 2006-12-14 2008-06-26 Tautatis, Inc. Compositions and methods for the treatment of cancer
EP2240475B1 (en) 2007-12-20 2013-09-25 Novartis AG Thiazole derivatives used as pi 3 kinase inhibitors
ES2326459B1 (es) * 2008-04-08 2010-05-28 Universidad De Oviedo Indolocarbazoles glicosilados, su procedimiento de obtencion y sus usos.
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
JP5963777B2 (ja) 2011-01-31 2016-08-03 ノバルティス アーゲー 新規ヘテロ環誘導体
CN104039790B (zh) 2011-10-28 2016-04-13 诺华股份有限公司 嘌呤衍生物及它们在治疗疾病中的应用
KR20150009540A (ko) 2012-05-16 2015-01-26 노파르티스 아게 Pi-3 키나제 억제제에 대한 투여 요법
SI3076969T1 (sl) 2013-12-06 2021-12-31 Novartis Ag Režim omderjanja izooblike alfa selektivnega zaviralca fosfatidilino- zitol 3-kinaze
CN104031052B (zh) * 2014-05-20 2016-06-08 中国科学院南海海洋研究所 抗生素Indimicins A–E及其制备方法和在制备抗肿瘤药物中的应用
US20180280370A1 (en) 2015-11-02 2018-10-04 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
CN119661614B (zh) * 2024-12-14 2026-03-17 中国海洋大学 吲哚咔唑类糖苷生物碱及其制备方法和在抗白血病药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552842A (en) 1983-01-28 1985-11-12 Bristol-Myers Company Process for producing rebeccamycin
US4487925A (en) 1983-01-28 1984-12-11 Bristol-Myers Company Rebeccamycin and process for its preparation
US4567143A (en) 1984-09-04 1986-01-28 Bristol-Myers Company Process for preparing 4'-deschlororebeccamycin
US4785085A (en) 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
WO1989007105A1 (fr) * 1988-02-04 1989-08-10 Kyowa Hakko Kogyo Co., Ltd. Derives de staurosporine
DE3924538A1 (de) 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
US5618809A (en) * 1989-12-14 1997-04-08 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes copiosa subsp. nov SCC 1951 ATCC 53856
IL97233A (en) 1990-03-06 1995-03-30 Bristol Myers Squibb Co Rebeccamycin analogs, their production and pharmaceutical compositions containing them
US5478813A (en) 1990-05-11 1995-12-26 Banyu Pharmaceutical Co., Ltd. Antitumor substance BE-13793C derivatives
NZ245203A (en) 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
US5589365A (en) 1991-11-29 1996-12-31 Banyu Pharmaceutical Co., Ltd. Process for producing glycosylated indolopyrrolocarbazole derivatives by culturing certain microorganisms
US5668271A (en) 1991-11-29 1997-09-16 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
DE69331228T4 (de) * 1992-09-21 2002-09-05 Kyowa Hakko Kogyo Co., Ltd. Heilmittel für thrombozytopenia
FR2696465B1 (fr) 1992-10-02 1994-12-23 Adir Nouveaux dérivés d'ellipticine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP3603322B2 (ja) 1992-12-14 2004-12-22 萬有製薬株式会社 インドロピロロカルバゾール誘導体の製造法
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
WO1995030682A1 (en) 1994-05-09 1995-11-16 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyprolocarbazole derivative
WO1996004293A1 (en) 1994-08-02 1996-02-15 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazoles
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
AU6888196A (en) * 1995-08-11 1997-03-12 Yale University Glycosylated indolocarbazole synthesis
HUP9903931A3 (en) 1996-08-22 2000-09-28 Bristol Myers Squibb Co Wallin Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
CO4940430A1 (es) * 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
FR2801054B1 (fr) 1999-11-17 2003-06-13 Adir Nouveaux derives de 12,13-(pyranosyl)-indolo[2,3-a]pyrrolo [3,4-c]carbazole et 12,13-(pyranosyl)-furo[3,4-c]indolo [2,3-a]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
US20020107237A1 (en) 2002-08-08
EP1326874A2 (en) 2003-07-16
US6677450B2 (en) 2004-01-13
JP2004523478A (ja) 2004-08-05
WO2002030941A2 (en) 2002-04-18
HUP0303279A3 (en) 2004-11-29
HUP0303279A2 (hu) 2004-01-28
WO2002030941A3 (en) 2002-10-03
CA2424971A1 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
AU710669B2 (en) Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
US6677450B2 (en) Topoisomerase inhibitors
US6653290B2 (en) Tumor proliferation inhibitors
US6610727B2 (en) Anhydro sugar derivatives of indolocarbazoles
US20030083271A1 (en) Topoisomerase I selective cytotoxic sugar derivatives of indolopyrrolocarbazoles
HK1024177B (en) Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
AU2002306809A1 (en) Topoisomerase I selective cytotoxic sugar derivatives of indolopyrrolocarbazoles
CZ54999A3 (cs) Cytotoxický aminosacharid a příbuzné sacharidové deriváty indolopyrrolokarbazolů
MXPA99001454A (en) Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application